The investment thesis for Viking Therapeutics now hinges on a single, high-stakes clinical event, according to market analysis. This shift in risk profile prompted Edmund Ingham, an analyst, to adjust his rating on the stock from “Buy” to “Hold” on March 19. The catalyst for this reassessment is the approaching Phase 3 readout for VK2735, the company’s dual GLP-1/GIP agonist candidate for obesity treatment. Investors are effectively making a binary bet on the outcome of this one pivotal data set.
A Market Poised for Volatility
With two Phase 3 trials for VK2735 nearly fully enrolled and a third for an oral formulation in the planning stages, the stock has entered a period of heightened sensitivity. As the data release draws nearer, the tolerance for any disappointing news diminishes, amplifying the potential impact of all new information on the share price.
This anticipation of volatility is reflected in market positioning. Short interest currently stands at 21.95% of the float, indicating a significant portion of the market is betting against the stock’s success, which can exacerbate price swings in either direction.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Despite the near-term uncertainty, the broader analyst consensus remains a “Moderate Buy,” with an average price target of $87.80. Compared to a recent trading price of $33.92, this implies a potential upside of approximately 159%. Individual ratings among covering analysts range from four “Strong Buy” recommendations to one “Sell.”
Intensifying Competitive Landscape
External pressures are simultaneously mounting. On the same day as the analyst downgrade, the U.S. Food and Drug Administration (FDA) approved a higher-dose version (7.2 mg) of Novo Nordisk’s Wegovy, which demonstrated superior weight reduction in studies. Furthermore, the FDA is set to decide on Eli Lilly’s oral obesity drug, Orforglipron, by April 2026, tightening the competitive race.
Viking Therapeutics enters this crucial period with a robust financial cushion of roughly $700 million in cash. This capital supports its ongoing clinical programs, which include VK2809 for NASH (Phase 2) and VK5211 for hip fracture rehabilitation (Phase 2 completed). Looking further ahead, a specific catalyst is scheduled for the third quarter of 2026: Phase 1 maintenance data from its leading metabolic candidates, expected to provide deeper insight into their long-term efficacy and safety profiles.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from March 20 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 20.
Viking Therapeutics: Buy or sell? Read more here...
